Interpretation of somatic POLE mutations in endometrial carcinoma
Pathogenic somatic missense mutations within the DNA polymerase epsilon (POLE) exonuclease domain define the important subtype of ultramutated tumours (‘POLE‐ultramutated’) within the novel molecular classification of endometrial carcinoma (EC). However, clinical implementation of this classifier re...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2020
|
| _version_ | 1826274029853474816 |
|---|---|
| author | León-Castillo, A Britton, H McConechy, MK McAlpine, JN Nout, R Kommoss, S Brucker, SY Carlson, JW Epstein, E Rau, TT Bosse, T Church, DN Gilks, CB |
| author_facet | León-Castillo, A Britton, H McConechy, MK McAlpine, JN Nout, R Kommoss, S Brucker, SY Carlson, JW Epstein, E Rau, TT Bosse, T Church, DN Gilks, CB |
| author_sort | León-Castillo, A |
| collection | OXFORD |
| description | Pathogenic somatic missense mutations within the DNA polymerase epsilon (POLE) exonuclease domain define the important subtype of ultramutated tumours (‘POLE‐ultramutated’) within the novel molecular classification of endometrial carcinoma (EC). However, clinical implementation of this classifier requires systematic evaluation of the pathogenicity of POLE mutations. To address this, we examined base changes, tumour mutational burden (TMB), DNA microsatellite instability (MSI) status, POLE variant frequency, and the results from six in silico tools on 82 ECs with whole‐exome sequencing from The Cancer Genome Atlas (TCGA). Of these, 41 had one of five known pathogenic POLE exonuclease domain mutations (EDM) and showed characteristic genomic alterations: C>A substitution > 20%, T>G substitutions > 4%, C>G substitutions < 0.6%, indels < 5%, TMB > 100 mut/Mb. A scoring system to assess these alterations (POLE‐score) was developed; based on their scores, 7/18 (39%) additional tumours with EDM were classified as POLE‐ultramutated ECs, and the six POLE mutations present in these tumours were considered pathogenic. Only 1/23 (4%) tumours with non‐EDM showed these genomic alterations, indicating that a large majority of mutations outside the exonuclease domain are not pathogenic. The infrequent combination of MSI‐H with POLE EDM led us to investigate the clinical significance of this association. Tumours with pathogenic POLE EDM co‐existent with MSI‐H showed genomic alterations characteristic of POLE‐ultramutated ECs. In a pooled analysis of 3361 ECs, 13 ECs with DNA mismatch repair deficiency (MMRd)/MSI‐H and a pathogenic POLE EDM had a 5‐year recurrence‐free survival (RFS) of 92.3%, comparable to previously reported POLE‐ultramutated ECs. Additionally, 14 cases with non‐pathogenic POLE EDM and MMRd/MSI‐H had a 5‐year RFS of 76.2%, similar to MMRd/MSI‐H, POLE wild‐type ECs, suggesting that these should be categorised as MMRd, rather than POLE‐ultramutated ECs for prognostication. This work provides guidance on classification of ECs with POLE mutations, facilitating implementation of POLE testing in routine clinical care. |
| first_indexed | 2024-03-06T22:37:14Z |
| format | Journal article |
| id | oxford-uuid:5a4facb5-150d-47e2-8367-63b1e14865cc |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:37:14Z |
| publishDate | 2020 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:5a4facb5-150d-47e2-8367-63b1e14865cc2022-03-26T17:15:09ZInterpretation of somatic POLE mutations in endometrial carcinomaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5a4facb5-150d-47e2-8367-63b1e14865ccEnglishSymplectic Elements at OxfordWiley2020León-Castillo, ABritton, HMcConechy, MKMcAlpine, JNNout, RKommoss, SBrucker, SYCarlson, JWEpstein, ERau, TTBosse, TChurch, DNGilks, CBPathogenic somatic missense mutations within the DNA polymerase epsilon (POLE) exonuclease domain define the important subtype of ultramutated tumours (‘POLE‐ultramutated’) within the novel molecular classification of endometrial carcinoma (EC). However, clinical implementation of this classifier requires systematic evaluation of the pathogenicity of POLE mutations. To address this, we examined base changes, tumour mutational burden (TMB), DNA microsatellite instability (MSI) status, POLE variant frequency, and the results from six in silico tools on 82 ECs with whole‐exome sequencing from The Cancer Genome Atlas (TCGA). Of these, 41 had one of five known pathogenic POLE exonuclease domain mutations (EDM) and showed characteristic genomic alterations: C>A substitution > 20%, T>G substitutions > 4%, C>G substitutions < 0.6%, indels < 5%, TMB > 100 mut/Mb. A scoring system to assess these alterations (POLE‐score) was developed; based on their scores, 7/18 (39%) additional tumours with EDM were classified as POLE‐ultramutated ECs, and the six POLE mutations present in these tumours were considered pathogenic. Only 1/23 (4%) tumours with non‐EDM showed these genomic alterations, indicating that a large majority of mutations outside the exonuclease domain are not pathogenic. The infrequent combination of MSI‐H with POLE EDM led us to investigate the clinical significance of this association. Tumours with pathogenic POLE EDM co‐existent with MSI‐H showed genomic alterations characteristic of POLE‐ultramutated ECs. In a pooled analysis of 3361 ECs, 13 ECs with DNA mismatch repair deficiency (MMRd)/MSI‐H and a pathogenic POLE EDM had a 5‐year recurrence‐free survival (RFS) of 92.3%, comparable to previously reported POLE‐ultramutated ECs. Additionally, 14 cases with non‐pathogenic POLE EDM and MMRd/MSI‐H had a 5‐year RFS of 76.2%, similar to MMRd/MSI‐H, POLE wild‐type ECs, suggesting that these should be categorised as MMRd, rather than POLE‐ultramutated ECs for prognostication. This work provides guidance on classification of ECs with POLE mutations, facilitating implementation of POLE testing in routine clinical care. |
| spellingShingle | León-Castillo, A Britton, H McConechy, MK McAlpine, JN Nout, R Kommoss, S Brucker, SY Carlson, JW Epstein, E Rau, TT Bosse, T Church, DN Gilks, CB Interpretation of somatic POLE mutations in endometrial carcinoma |
| title | Interpretation of somatic POLE mutations in endometrial carcinoma |
| title_full | Interpretation of somatic POLE mutations in endometrial carcinoma |
| title_fullStr | Interpretation of somatic POLE mutations in endometrial carcinoma |
| title_full_unstemmed | Interpretation of somatic POLE mutations in endometrial carcinoma |
| title_short | Interpretation of somatic POLE mutations in endometrial carcinoma |
| title_sort | interpretation of somatic pole mutations in endometrial carcinoma |
| work_keys_str_mv | AT leoncastilloa interpretationofsomaticpolemutationsinendometrialcarcinoma AT brittonh interpretationofsomaticpolemutationsinendometrialcarcinoma AT mcconechymk interpretationofsomaticpolemutationsinendometrialcarcinoma AT mcalpinejn interpretationofsomaticpolemutationsinendometrialcarcinoma AT noutr interpretationofsomaticpolemutationsinendometrialcarcinoma AT kommosss interpretationofsomaticpolemutationsinendometrialcarcinoma AT bruckersy interpretationofsomaticpolemutationsinendometrialcarcinoma AT carlsonjw interpretationofsomaticpolemutationsinendometrialcarcinoma AT epsteine interpretationofsomaticpolemutationsinendometrialcarcinoma AT rautt interpretationofsomaticpolemutationsinendometrialcarcinoma AT bosset interpretationofsomaticpolemutationsinendometrialcarcinoma AT churchdn interpretationofsomaticpolemutationsinendometrialcarcinoma AT gilkscb interpretationofsomaticpolemutationsinendometrialcarcinoma |